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Achieving a timely diagnosis for teenagers
and young adults with cancer: the ACE “too
young to get cancer?” study
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Aoife Nechowska1, Alison Wint3 and Michael C. G. Stevens1,4*
Abstract
Background: Time to diagnosis (TTD) concerns teenagers and young adults (TYA) with cancer and may affect
outcome.
Methods: Healthcare records from 105 TYA in a regional cancer service were assessed to document events from
1st symptom to treatment start. Detailed pathway construction was possible for 104 patients and allowed a
multidisciplinary panel review of each pathway with assessment of good practice and lessons for the future.
Results: 1st presentation was to primary care in 86, and 93% consulted in primary care before diagnosis.
Routes to Diagnosis were 45% via urgent 2 Week Wait pathways and 38% as emergency referrals. Total
Interval (time from 1st presentation to treatment start) was median 63 (range 1–559) days, varying within/
between diagnoses. Patient interval (time from 1st symptom to 1st presentation) was longest for lymphoma,
carcinoma and bone tumour (medians: 9, 12, 20 days). Overall, time in primary care was short (median 3,
range 0–537 days) compared to secondary care (median 29, range 0–195 days) and longest for lymphoma,
carcinoma, brain/CNS (medians: 10, 15, 16 days). Specialist Care interval (time from 1st specialist visit to
treatment start) was longest for bone, brain/CNS, lymphoma, carcinoma (medians: 30, 33, 36, 48 days). 40%
pathways were rated as showing good/best practice but 16% were less than satisfactory. Continued safety-
netting/support was identified from primary care but analysis suggested opportunities for improvement in
transition through secondary care.
Conclusions: Previous reports of prolonged TTD have focused on delay in referral from primary care but this
study suggests that this might be reduced by optimising management in secondary care.
Keywords: TYA, Time to diagnosis, Routes to diagnosis, Primary care, Secondary care
Background
Cancer is the commonest cause of disease-related death in
Teenagers and Young Adults (TYA - age 15 to 24 years)
[1]. Timely diagnosis is a major concern for young people
and their families [2–6] and despite limited data to link
prolonged time to diagnosis (TTD) with adverse survival
[7–9], actual or perceived delay may significantly impact
patient experience, quality of survival, psychological health
and future trust in healthcare.
Factors influencing the length of the diagnostic path-
way are complex. Cancer has been considered to be a
rare event in children and young people and there may
still be an under-recognition of the possibility of its diag-
nosis amongst health professionals (“too young to get
cancer?”). However, the incidence of cancer in young
people age 15–24 years in the United Kingdom rose by
33% between 1992 and 95 and 2013–15 to an age stan-
dardised incidence rate of 298/million; and the cumula-
tive risk of a diagnosis of cancer in the TYA age span
now approaches 1 in 200 individuals [10]. Issues may
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also arise in relation to the non-specific nature of symp-
toms associated with the most frequently encountered
diagnoses encountered by TYA and the difficulties some
young people experience in navigating the health care
system [2, 11–14].
Work to map the diagnostic journey (Routes to Diag-
nosis – RTD) for adults with cancer has highlighted vari-
ability in Time to Diagnosis (TTD) between diagnostic
groups [15] and suggests that longer TTD may reduce
survival [16]. Particular emphasis has been placed on
strategies to improve the recognition of cancer in pri-
mary care [17–19] and attention paid to the positive pre-
dictive value of ‘alert’ symptoms [20]. Conclusions of
such studies may not be easily transferrable to young
people: although analysis of pre-diagnostic consultations
shows positive associations between subsequent cancer
diagnosis and both consultation frequency and alert
symptoms, the resulting positive predictive values are
too low to be of clinical value [21–24].
Specific studies exploring RTD and TTD within the
TYA age range are limited. Recently published data from
the BRIGHTLIGHT cohort, a study of TYA patients re-
cruited across England, correlated patient-derived recall
of symptom onset and healthcare consultation with date
of diagnosis from cancer registry records [25] and
highlighted that sociodemographic factors and tumour
type significantly influenced pre-referral primary care
consultation rates and TTD. The relationship between
TTD and cancer type in TYA has also been reported by
others [13, 26]. Other studies suggest low utilisation of
the 2 Week Wait (TWW) referral pathway in TYA, and
an excess of emergency referral [27] but, in contrast
to adult data [28], there is currently no evidence that
emergency referral for TYA adversely affects survival.
Processes in secondary care may also contribute to
increased TTD [7] but have not been formally studied
in TYA.
Methods
Aim, design and setting
The “Too Young To Get Cancer?” study was a service
evaluation project initiated within the ACE (Accelerate,
Coordinate, Evaluate) programme established in England
in 2014 with support from NHS England, Cancer Re-
search UK and Macmillan Cancer Support [29]. The ob-
jective was to better understand referral pathways in a
cohort of newly diagnosed patients referred to a regional
care network for TYA cancer in the South West of Eng-
land. Existing referral policies were in line with those
mandated by the specification for TYA cancer services
set within NHS England. Time to diagnosis had been
identified as a priority concern by patients involved in
previous service development within the network [30].
Patient recruitment, permissions and access to healthcare
records
All newly diagnosed patients referred within the regional
TYA cancer care network between October 2014 and
April 2016 were eligible but were approached only after
current status had been verified by a TYA Clinical Nurse
Specialist (CNS). Written permission to access health-
care records was obtained from all verified patients (or
from next of kin if deceased).
The Caldicott Guardians1 (individuals responsible for
protecting the confidentiality of personal data) at each
NHS hospital Trust2 participating in the TYA network
agreed to the extraction of data from hospital records.
Access to primary care records was arranged with the
consent of each patient’s general practitioner (GP). The
inclusion of records from deceased patients was
attempted to avoid bias. Next of kin were approached by
the healthcare professional identified to have the closest
relationship and written permission to access health care
records was obtained for all deceased patients included
in the study.
Data collection
All records in primary and secondary care were reviewed
by one investigator (HP) using a pro forma constructed
by clinical members of the study team based on experi-
ence of patient diagnostic pathways acquired from their
clinical experience.
The aim was to collect both qualitative and quantita-
tive data about each patient’s pathway (including free
text to provide context and detail) so that the entire
route to diagnosis could be articulated as a coherent
story, yet also summarised as a structured chain of
events. These events included dates of all the following:
consultations (including any scheduled but which did
not take place); referrals; investigations; non-cancer
treatments; diagnosis; multidisciplinary team (MDT) dis-
cussions; and first cancer treatment. Free text detail per-
mitted inclusion of information such as: who initiated
each event; what type of event it was (e.g. emergency or
routine referral); where each event took place (e.g. pri-
mary care, hospital emergency department, hospital out-
patient clinic); symptomatology recorded; and the
outcomes or action reported (e.g. safety netting, planned
review, investigation, referral).
Date of diagnosis was defined as the date the specimen
resulting in the first histological or cytological confirm-
ation of malignancy was taken.
The data abstracted from the clinical records were
sorted chronologically into a bespoke database created
specifically to manage these data and which included the
facility to link comments and free text observations to
each recorded event.
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Individual pathway maps and panel reviews
The data collected for each patient was used to con-
struct an individual pathway map which summarised all
events against a timeline (in days) and identified transi-
tions between primary and secondary care. Key events
were as described in the Aarhus Statement [31] and de-
fined intervals along the diagnostic pathway were as de-
scribed by Oleson et al. [32].
Two exemplar pathway maps are shown as Tables 1
and 2. In each case, the shaded boxes represent all
events identified in relation to specific dates in the pa-
tient’s route to diagnosis. Events significant to the under-
standing of the pathway are identified as a short
summary statement but, for reasons of space, full details
are not shown. Note that the days of each pathway
shown are not consecutive (also for reasons of space)
but that full details of each event and every date (with
the corresponding day of the week) were available in the
versions presented for panel discussions.
All pathway maps were reviewed by a panel of senior
clinicians including consultants in adult, TYA and paedi-
atric haematology/oncology, a senior TYA nurse and a
general practitioner. The aim of the panel review was to
confirm key events in each pathway and to record exam-
ples of good practice; missed opportunities for potential
earlier diagnosis; and whether, and at which point, an
intervention to effect earlier diagnosis might have been
possible. The panel also sought to identify potential in-
terventions that could have improved transition through
the pathway and/or improve patient experience.
The first date of presentation to primary care was
identified by agreement within the panel as the time
point at which the patient first presented with symptoms
which, in retrospect, were likely to be related to their
final cancer diagnosis.
The panel’s assessment was guided by a set of pre de-
termined criteria relating to each component of the
diagnostic pathway (Table 3). These criteria were estab-
lished and agreed by the panel prior to starting work on
pathway review. They were based on a consensus view
of issues that might be relevant to decisions taken along
the route to cancer diagnosis and were informed by the
panel members’ own clinical practice and experience.
A final outcome (“clinical bottom line”) was discussed
by the panel for each pathway and documented as its
consensus view, using an overall rating statement similar
to that used by the National Confidential Enquiry into
Patient Outcome and Death (NCEPOD) [33] and shown
in the legend to Fig. 1.
Outcomes and feedback
The study protocol did not include a plan to collect or
analyse feedback received from the dissemination of the
study’s findings although outcomes and lessons learned
from the study were shared in a number of settings. This
included a dissemination event to which all those who
had participated (professionals, patients and next of kin)
were invited; to staff at the hospitals in which patient re-
cords were accessed; to primary care staff at a regional
information cascade event; to the TYA community at
national and international meetings; and to other ACE
programme participants.
Reports of individual patient pathways were con-
structed for sharing with the clinicians involved. An
anonymised extract of the front page of one such report
is shown as Fig. 2: note that each report was accompan-
ied by a narrative explanation of factors considered rele-
vant to the patient’s transition through the pathway and
to the ‘Clinical Bottom Line’ conclusion reached by the
panel.
Statistical analysis
As conclusions were based on data obtained from an
audit of individual patient records across a range of dif-
ferent diagnoses without a comparator group or inter-
vention, formal statistical analysis was utilised only to
compare responders who allowed their records to be
accessed with those who did not (Chi squared test). Sim-
ple descriptors were used to aggregate data into broad
groups by diagnosis, age and gender. Pathway intervals
were expressed as median and range.
Ethical approval
In line with guidance from the NHS Health Research
Authority which confirms that formal ethical review is
not required for audit and service evaluation [34], formal
research ethical approval was not requested. All TYA eli-
gible for the study were nevertheless approached with
written information about the purpose of the study and
written consent was required to access health care
records.
Results
Patients
186 patients were identified as potentially eligible for the
study of whom 166 (89%) were approached to partici-
pate; 20 patients were not approached based on the
judgement made by the relevant TYA CNS although
reasons were not recorded. Permission was received
from 105/166(63%) but data from one patient was con-
sidered insufficient to evaluate the pathway. The char-
acteristics of the 104 patients included in the study
were: 54(52%) male; 34(33%) aged 15–18 years; and
97(93%) self-identified as white British. Diagnoses were:
Lymphoma 29(28%); Carcinoma 21(20%); Leukaemia
18(17%); Germ cell tumours 10(10%); Brain/CNS tu-
mours 7(7%); Bone tumour 7(7%); Soft tissue sarcoma
6(6%); Melanoma 5(5%); and ‘other’ 1 (Wilms’ tumour).
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Table 1 Example pathway 1 (Male, age 19 years at diagnosis of Ewing’s sarcoma) and explanatory narrative
History: Presented to GP with a 6 month history of lumps in the groin and complaining of pain in the lower back for up to 2 years. He had a previous history of
recreational drug use. He was found to have inguinal lymphadenopathy and was tender over the lumbosacral spine
Pathway: Blood tests were obtained and an MRI scan was requested and referral made to a local musculoskeletal clinic on Day 2. In the meantime he attended his
GP surgery on multiple occasions for pain management. A plain x ray of the hip was obtained after attending the musculoskeletal clinic (day 61) and a non-
urgent referral made to the orthopaedic clinic. This did not take place until day 128 when urgent arrangements were made for MRI (which confirmed a large
pelvic tumour) and CT chest (which showed metastases). Transfer was requested to a surgical orthopaedic oncology centre where a biopsy was obtained on day
141. Staging investigations and multiple MDT discussions took place, initially because of concern that re biopsy might be required. These involved both
institutions and a national MDT. Chemotherapy was commenced on day 170. Throughout this time, he continued to attend his GP surgery for pain management
Intervals:
Total interval (Primary care interval (1st seen to 1st referral) = 6 days
Secondary care interval (1st referral to start of treatment) = 164 days
Diagnostic interval (1st seen to diagnosis (date of biopsy)) = 141 days
Treatment interval (Diagnosis (date of biopsy) to start of treatment) = 29 days
Key points arising in the panel discussion:
1. Primary care: despite early referral to secondary care, an appointment for the musculoskeletal clinic was not followed up despite continuing attendance for pain
control; nor was the early request made for an MRI expedited despite the severity of symptoms. The patient’s previous history of drug abuse may have affected
judgement about his analgesic requirement
2. Secondary care: retrospectively, it was apparent that there had been a failure to recognise an abnormality on the plain x ray obtained at the musculoskeletal
clinic and further assessment at an orthopaedic clinic was not prioritised, resulting in a 67 day delay before the patient was seen and appropriate radiology
obtained. Despite rapid onward referral to a specialist orthopaedic oncology centre for biopsy, a further 29 days passed from the date of biopsy to the start of
chemotherapy. It was felt that staging investigations and MDT discussions should all have been achieved more quickly, particularly as the patient had metastatic
disease when the diagnosis was established
“Clinical bottom line” – panel decision: Less than satisfactory
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Table 2 Example pathway 2 (Male, age 23 years at diagnosis of Hodgkin’s lymphoma) and explanatory narrative
History: Presented to a local emergency department with a 6 week history of feeling unwell, with cough, evolving cervical lymphadenopathy and recent onset of
night sweats. He had had no prior contact with primary care and was living away from home at the time
Pathway: Patient was admitted from the emergency department, radiology and blood tests taken and a biopsy was performed the following day which confirmed
Hodgkin’s Lymphoma. The patient elected to return home for treatment. His GP was informed on Day 4 and a referral made to his local hospital where he was
seen as an outpatient for reassessment and completion of staging investigations on Day 15. The diagnosis and treatment plan were discussed at the local MDT on
Day 21 and chemotherapy commenced on Day 35 after further discussion with the patient and insertion of a PICC line
Intervals:
Primary care interval (1st seen to 1st referral) = Not applicable
Secondary care interval (1st referral to start of treatment) = 34 days
Diagnostic interval (1st seen to diagnosis (date of biopsy)) = 2 days
Treatment interval (Diagnosis (date of biopsy) to start of treatment) = 33 days
Key points arising in the panel discussion:
1. This patient presented as an emergency and was diagnosed without delay. The time taken to commence treatment was longer than might otherwise have
been necessary only because he was living away from home and elected to be referred back to his local hospital for completion of staging, treatment planning
and treatment
“Clinical bottom line” decision: Best practice
Table 3 Criteria taken into consideration by panel in assessing each event in the pathway
Initial diagnostic assessment Diagnostic test performance
and interpretation
Diagnostic follow up and consultation
Primary care Secondary care
Patient Language. Geography. Comorbidity.
Psycho-social factors.
Non adherence Passive/Active FU of results.
Unsafe-safety netting.
Inconsistent symptoms or
resolution of symptoms.
Passive/Active FU of results.
Unsafe-safety netting.
Inconsistent symptoms or
resolution of symptom
Healthcare
Professional
Inadequate history and/or
examination. Cognitive factors,
unfamiliarity with cancer
presentation. Comorbidities.
Referral norms. Continuity of care.
Misinterpretation of results,
false negative. Lack/delay of
FU of results. Deficient
investigation strategy/wrong
test. Communication.
Over reliance on patient to
re-present. Timely FU.
Communication. Coordination
failures. Lack of appreciation
or FU of abnormal test result.
Continuity of care.
Over reliance on patient to
re-present. Timely FU.
Communication. Coordination
failures. Lack of appreciation
or FU of abnormal test result.
Continuity of care.
System Rigid consultation norms. Access/
system capacity constraints.
Access to diagnostic tests.
Administrative failure in booking
Lack of system to deal with
failure to attend. Diagnostic
testing process complexity.
Lack of ownership of results.
Accountability for the patient
as they progress through the
diagnostic pathway.
Accountability for the patient
as they progress through the
diagnostic pathway.
Disease Atypical symptoms and/or
presentation.
False negatives.
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Comparison with the 61 non-responders to the invita-
tion showed that response rates varied by diagnosis
(highest (> 70%) amongst those with lymphoma, bone
tumour and carcinoma and lowest (< 50%) in those
with germ cell tumour and melanoma) but only a def-
icit in the number of patients with germ cell tumours
Fig. 1 Clinical bottom line by diagnosis
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Fig. 2 Front page from a patient summary report prepared for clinicians involved in care
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in the responder group reached statistical significance
(p < 0.02). Three patients were included in the study
after their death with the permission of their next of
kin.
Data collection, pathway preparation and panel review
Data were collected from 66 GP practices and from 9
hospital Trusts over a 10 month period ending in Sep-
tember 2016. The complexity of pathways varied widely;
for example, some only included 10 events, whereas in
one patient 69 events were identified. All pathways were
discussed by the panel using the criteria shown in Table
3. The panel convened nine times; on average, 25 min
was required for the evaluation and discussion of each
pathway, although in complex cases this took up to 1 h.
Patient pathway analysis
The first presentation relating to the cancer diagnosis
was to primary care in 86%; 7% to hospital Accident &
Emergency (A&E) departments; 4% to other healthcare
professionals; and 3% unknown/unclear. Overall, cancer
was suspected at first presentation in 34% patients and
varied by diagnostic group - highest in germ cell tu-
mours (67%) of whom 9/10 were men presenting with
testicular mass. Cancer was not suspected at first pres-
entation in any patient (n = 7) with bone sarcoma.
(Table 4).
Primary care
Whilst 86% had consulted primary care prior to referral
to secondary care, 93% consulted at some point prior to
diagnosis, many on multiple occasions. Some patients
continued to consult in primary care after diagnosis and
up to the point of treatment. The frequency and variabil-
ity of primary care consultation is shown in Fig. 3; for
example, 15/25(60%) patients with lymphoma who had
consulted primary care had done so ≥5 times before
start of treatment. Patients also accessed out of hours
Fig. 3 Number of primary care contacts from 1st presentation to start of treatment by type of cancer diagnosis i.e. throughout the Total Interval
(each bar represents one patient)
Table 4 Place and suspicion of cancer at first presentation, by diagnosis
Diagnosis Pathway data (n) Primary Care (n) A&E (n) Other (n) Unknown (n) Cancer suspected (%)
Lymphoma 29 25 3 0 1 44
Carcinoma 21 16 0 3 2 21
Leukaemia 18 16 2 0 0 33
Germ Cell 10 9 0 0 1 67
Brain / CNS 7 5 1 1 0 14
Bone Tumour 7 6 1 0 0 0
Melanoma 6 6 0 0 0 60
Soft Tissue 5 5 0 0 0 33
Other 1 1 0 0 0 0
Total 104 89 (85.6%) 7 (6.7%) 4 (3.8%) 4 (3.8%) Overall 34%
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services, used telephone consultations and presented to
A&E departments, sometimes before consulting their
own GP.
Routes to diagnosis
Using established RTD definitions [14], 45% of patients
were referred from primary care via urgent 2 Week Wait
(TWW) pathways; 38% emergency referrals; 11% routine
referrals; 6% other outpatient routes; and 1 patient via
screening.
RTD varied by diagnostic group (Fig. 4). All malignant
melanoma patients and over half of lymphoma patients
presented via TWW compared with only 1/7 bone sar-
coma and 0/7 of the brain/CNS tumour patients.
Of the 40 (38%) patients who presented as emergen-
cies, 16 had leukaemia (89% of all leukaemia patients).
In considering diagnoses other than leukaemia, 22/86
(26%) presented as emergencies. Those with brain/CNS
tumours (4/7, 57%), carcinoma (6/21, 29%) and lymph-
oma (6/29, 21%) were the largest contributors to this
group. Overall, 37% of all patients referred via an emer-
gency route were considered by the panel to have had
opportunities for an earlier referral by another route.
Total interval
Table 5 shows median duration of each interval by diag-
nosis. The longest total interval (time from first presen-
tation to start of treatment) was in patients with
melanoma (median 99 days (range 70–392)) and bone
sarcoma (86, (45–169)), and the shortest intervals in pa-
tients with leukaemia (7 (1–146)) and germ cell tumours
(29 (6–559)) but with variability between and within
each diagnostic group (Fig. 5a).
Patient interval
Time from first symptom to first presentation was gen-
erally very short (Table 5) other than for bone tumour,
carcinoma and lymphoma. Panel analysis suggested that
symptoms in some patients with these diagnoses could
have led to an earlier recognition of cancer.
Time in primary and secondary care
Figure 5b illustrates the relative time spent in primary
and secondary care (detailed data from Table 5). The
primary care interval was greatest in brain/CNS tumours
(median 16 days), carcinoma (15 days) and lymphoma
(10 days). The time spent in secondary care (i.e. from re-
ferral to start of treatment) also varied and was shortest
Fig. 4 Routes to Diagnosis by cancer type
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a)
b)
c)
Fig. 5 a Total Interval (vertical axis capped at 300 days) by individual patient and diagnosis. b Median duration of Primary Care Interval and
Secondary Care Interval (days). c Median duration of Diagnostic Interval and Treatment Interval (days)
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in leukaemia (median 3 days) but longest in melanoma
(median 84 days), bone tumour (79 days), carcinoma (53
days), and lymphoma (45 days).
Patients with bone tumour spent very little time in pri-
mary care (median 1 day) although they had one of the
longest Total Intervals (median 86 days). Pathway ana-
lysis suggested that prompt referral to secondary care,
frequently to musculoskeletal clinics, accounted for this
despite lack of a suspicion of cancer.
Patients with melanoma had the longest Total Interval
(median 99 days) but also spent very little time in pri-
mary care. This was accounted for by a long Treatment
Interval because the start of treatment was defined as
the date of wide local excision rather than that of the ex-
cision biopsy undertaken after a (short) Referral Interval.
Other than melanoma, patients with carcinoma,
lymphoma, brain/CNS tumours and bone tumours had
the longest Specialist Care Interval (i.e. from the time of
first specialist visit to start of treatment – median 48, 36,
33 and 30 days respectively). These patients were often
subject to sequential investigation and/or repeated MDT
discussion. Figure 5c highlights the relative times spent
awaiting a diagnosis from the time of first healthcare
contact (Diagnostic Interval) and before starting treat-
ment (Treatment Interval). Patients with carcinoma,
bone tumour and lymphoma all experienced intervals of
approximately 3 weeks before starting treatment (median
Treatment Intervals 22, 21 and 18 days respectively).
Treatment Intervals were shortest in leukaemia and in
germ cell tumours (orchidectomy providing a simultan-
eous diagnostic and treatment event in 9/10).
General themes
Panel discussion highlighted a number of general themes
about patient management including: uncertain account-
ability for, and ineffective on-going management of, pa-
tients within secondary care pathways; timeliness of
radiological reporting and delayed response to positive
investigations; and non-adherence to National Institute
of Clinical Excellence (NICE – now the National Insti-
tute for Health and Care Excellence) referral guidance
[35]. Concern was also identified about the impact of
timely decision-making on patient experience and lack
of consistent oversight in the management of pain and
other symptoms prior to diagnosis. It was clear that a
number of patients continued to rely on primary care
for clarification of the management plan despite being in
secondary care.
Final outcome (“Clinical Bottom Line”)
All pathways were assessed in line with NCEPOD defini-
tions (Fig. 1), 94%(98/104) were considered informative
of which 40% represented good or best practice; 44% as
requiring room for improvement (i.e. that aspects of
clinical and/or organisational care could have been bet-
ter); and 16% as less than satisfactory. This varied be-
tween diagnostic groups. No bone tumour pathway and
fewer than 30% of lymphoma, brain/CNS and carcinoma
pathways were classified as good/best practice. In com-
parison, 78% of leukaemia pathways and 67% of germ
cell tumour pathways were deemed to illustrate good/
best practice.
Discussion
This study confirms the complexity and variability of the
diagnostic pathways traversed by TYA with cancer, with
differences within and between different diagnostic
groups. The proportion of different diagnoses included
in the analysis broadly reflects the pattern of disease in
the TYA age range although there were fewer than ex-
pected brain/CNS tumour patients in the cohort, the
reason for which was unclear. This may have repre-
sented variability in the incidence of brain/CNS tumours
diagnosed and / or referred to the TYA service during
the period of the study.
Although the majority of patients presented promptly
to primary care with symptoms relating to their cancer,
patients with carcinoma, lymphoma and bone tumours
experienced longer patient interval suggesting that, in
retrospect, diagnosis might have been recognised earlier.
Many consulted frequently, some even after referral had
been made to secondary care. Overall, cancer was sus-
pected in 34% patients at the time of their first presenta-
tion. This was highest for germ cell tumour, melanoma
and lymphoma but suspicion was low for those subse-
quently diagnosed with carcinoma, perhaps as a result of
the heterogeneity of the sites involved. It was also low in
those with brain/CNS tumours and was not considered
at all in any of the patients subsequently diagnosed with
bone tumour. This is consistent with evidence that TYA
with bone and brain tumours are amongst those most
likely to experience longer times to diagnosis [2, 13, 24].
In considering RTD, contrary to other data suggesting
low TWW usage in the TYA age group [27], 45% of pa-
tients were referred by this route including all of those
with melanoma and more than half of all those with car-
cinoma, lymphoma and soft tissue sarcoma. High use of
emergency referral was confirmed (38% overall), includ-
ing nearly all patients with leukaemia (appropriate for
this diagnosis). Excluding leukaemia, 26% of patients
with other diagnoses presented via emergency referral
but, overall, the review panel felt that 37% of diagnoses
identified after emergency presentation could have been
made earlier by another route.
The total pathway was seen to vary considerably
within and between the diagnostic groups but exceeded
2 months for all except those with leukaemia, which usu-
ally presents with rapidly evolving symptoms and signs,
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germ cell tumour for which suspicion of cancer was high
at first presentation, and soft tissue sarcoma - a small
group characterised by disease at different sites for
which it was difficult to draw specific conclusions.
Despite having high rates of suspicion of cancer at re-
ferral, those subsequently diagnosed with melanoma and
lymphoma also had long total pathways. The duration of
the pathway for melanoma may be seen as an artefact
resulting from the use of the date of wide local excision
as the date of definitive treatment.
Overall, the data suggest that many patients in diag-
nostic groups typical of the TYA age group do not pass
through the secondary care pathway as smoothly as
might be hoped or expected and suggest a need for
greater focus on time spent in secondary care before
diagnosis and start of treatment. This particularly ap-
plied to patients with lymphoma, carcinoma and bone
tumours, groups with the longest diagnostic and treat-
ment intervals. Patients with bone tumours also had the
longest referral interval, the majority of which was
accounted for by the duration of the period between re-
ferral to secondary care and review by a specialist after
which the diagnosis was considered and specifically
investigated.
By way of an example, patients with lymphoma, the
most common form of cancer in TYA (and the largest
subset in the study) were shown to have a relatively
short primary care interval and a high suspicion of can-
cer at first presentation but then spent a median of 36
days from first specialist consultation, and 18 days from
diagnostic biopsy, to start of treatment. Panel review
identified examples of unnecessary delay including diffi-
culty in accessing and reporting radiological investiga-
tions (for example, reporting an abnormal chest x ray
and referring the patient back to the initial clinician to
order a CT scan when it was clear that this would be re-
quired) – reflecting a more general concern about earlier
access to appropriate diagnostics identified in the litera-
ture relating to earlier cancer diagnosis [3, 13]. Other
concerns included the need for open biopsy after failure
of fine needle aspiration cytology to establish diagnosis
and transfer between different MDTs (for example refer-
ring from head and neck MDT to haematology MDT
without progressing required investigations such as a
PET CT scan despite confirming the diagnosis of Hodg-
kin’s lymphoma).
There are weaknesses in this study, as there are in
methodologies used by early diagnosis researchers in
general [36, 37]. Specifically, we recognise that 11% of
patients eligible for approach about participation in this
study were excluded on the advice of their local nurse
specialist. No information was collected about the rea-
sons and the judgement of the nurses was accepted
when determining whether it was reasonable to
approach a patient over a study which could raise con-
cerns about time taken to achieve diagnosis. It was
therefore not possible to characterise details of this
group in relation to those who were approached. Indi-
vidual diagnostic groups were relatively small and the
conclusions reached may not be completely transferable
to other settings.
The project was not designed either to relate TTD or
RTD to outcome or to capture the young people’s per-
spectives on their diagnostic experience. TYAs’ inter-
pretation of their RTD may differ from that of the
professionals involved and some may benefit from the
opportunity to discuss their pre-diagnosis journey either
with their GP or another relevant healthcare profes-
sional. This could be important in re-establishing rela-
tionships to support positive experience in future
healthcare encounters.
Conclusions
In contrast to previous concerns about the need to im-
prove the recognition of alert symptoms and reduce
time to referral from primary care, there was little evi-
dence of consistent delay in primary care and patterns of
repeated consultation seen after the date of referral and/
or diagnosis suggest that support and safety netting was
being offered. Achieving timely diagnosis and a prompt
start to treatment is dependent both on early referral to,
and efficient management in, secondary care. Added to
this are the challenges young people report in navigating
healthcare systems, and there is a case to be made for
improving advocacy, support and pathway management
for young people facing a possible diagnosis of cancer.
Endnotes
1A Caldicott Guardian is a senior person responsible
for protecting the confidentiality of people’s health and
care information and making sure it is used properly. In
the United Kingdom, all NHS organisations must have a
person in such a role.
2An NHS Trust is an organisational unit within the
National Health Service in England, generally serving ei-
ther a geographical area or a specialised function (e.g. a
hospital). In any particular location, there may be several
trusts involved in the different aspects of healthcare for
its residents.
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